Patent ID: 9498542
Filing Date: 2016-11-22
CPC Classification: A61K,A61P,B82Y,C07K

Claim Text:
1. A method of delivering a cytokine comprising: a) obtaining a cytokine-antibody complex comprising; (i) a cytokine moiety attached to a DDD (dimerization and docking domain) moiety, wherein the amino acid sequence of said DDD moiety is residues 1-44 of human protein kinase A (PKA) RIIα, wherein the cytokine moiety is selected from the group consisting of MIF (macrophage migration inhibitory factor), IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18, interferon-α, interferon-β, G-CSF, GM-CSF, Flt-3, erythropoietin, thrombopoietin, vascular endothelial growth factor, (VEGF) fibroblast growth factor (FGF), insulin, and hGH; and (ii) an antibody moiety attached to an AD (anchor domain) moiety, wherein the amino acid sequence of the AD moiety is from a human AKAP (A-kinase anchoring protein), wherein the DDD moieties form a dimer that binds to the AD moiety to form the complex, wherein the antibody moiety binds to a human antigen selected from the group consisting of carbonic anhydrase IX, CSAp, CD1, CD1a, CD2, CD3, CD5, CD8, CD14, CD15, CD16, CD19, IGF-1R, CD20, CD21, CD22, CD23, CD25, CD30, CD33, CD37, CD38, CD40, CD45, CD46, CD52, CD55, CD59, CD64, CD70, CD74, CD79a, CD80, CD83, CD95, CD138, CD147, CD154, PSMA, CEACAM-5, CEACAM-6, ED-B fibronectin, Flt-3, folate receptor, HMGB-1 (high mobility group protein B-1), hypoxia inducible factor (HIF), MAGE, MUC1, MUC2, MUC3, MUC4, NCA-90, EGP-1, EGP-2, HLA-DR, tenascin, Le(y), TAC, Tn antigen, Thomson-Friedenreich antigen, tumor necrosis antigens, VEGFR, and EGFR; and b) administering the complex to a human subject.